UroMems announced that it received FDA investigational device exemption (IDE) approval to begin a first-of-its-kind trial for its smart implant.
MINNEAPOLIS, July 17, 2025 /PRNewswire/ — Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the full commercial launch of EVA, its next-generation sensing technology, in the United States (U.S.). EVA received U.S. Food & Drug Administration (FDA) approval in December 2024 and is compatible with all commercially implanted Evoke® SmartLoop™ System patients.
Johnson & Johnson (NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.
Learn how “robot metabolism” allows machines to take material from their surroundings to “grow” and to “heal.”
Two university hospitals are pioneering new ways to expand lifesaving heart transplants for adults and babies—advances that could help recover would-be heart donations that too often go unused.
A scientific team supported in part by the National Institutes of Health (NIH) has developed a new, ultra-high-resolution brain imaging system that can reconstruct microscopic brain structures that are disrupted in neurological and neuropsychiatric brain disorders.
Duke Health has pioneered a world’s-first technique that could expand the donor pool for pediatric heart transplants in the U.S. by up to 20%—offering new hope to families on the waitlist.
Sensome, the pioneer of microsensing technology for real-time, in situ tissue analysis, today announced the publication of a study in Science Advances unveiling an innovative methodology using its technology to noninvasively monitor cell spatiotemporal dynamics involved in cancer progression in a real-time and label-free manner, which can provide new insights for cancer diagnosis and treatment.
Artificial intelligence (AI) models trained on large datasets are increasingly seen as the key to unlocking personalized treatments for brain disorders. An important bottleneck for scaling AI is the cost of data collection. This raises a fundamental dilemma: is it more cost-effective to scan more people for a short time, or fewer people for longer?
Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients with early-stage, slow-progressing mild cognitive impairment—a condition that can progress to Alzheimer’s.